Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Allogeneic CAR-T Cells: More than Ease of Access?
Charlotte Graham, Agnieszka Jóźwik, Andrea Pepper, et al.
Cells (2018) Vol. 7, Iss. 10, pp. 155-155
Open Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq, Christopher S. Hackett, Renier J. Brentjens
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 3, pp. 147-167
Open Access | Times Cited: 1137
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah, Ajai Chari, Emma C. Scott, et al.
Leukemia (2020) Vol. 34, Iss. 4, pp. 985-1005
Open Access | Times Cited: 383
Artificial Intelligence and Personalized Medicine
Nicholas J. Schork
Cancer treatment and research (2019), pp. 265-283
Closed Access | Times Cited: 350
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
Neha N. Parayath, Sirkka B. Stephan, Amanda Koehne, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 291
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu, Qihang Sun, Xiaoqian Liang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 269
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana, Saar Gill
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 184
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
Abigail K. Grosskopf, Louai Labanieh, Dorota D. Klysz, et al.
Science Advances (2022) Vol. 8, Iss. 14
Open Access | Times Cited: 160
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Ahmet Yılmaz, Hanwei Cui, Michael A. Caligiuri, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 148
Cancer immunotherapy: Challenges and limitations
Sina Taefehshokr, Aram Parhizkar, Shima Hayati, et al.
Pathology - Research and Practice (2021) Vol. 229, pp. 153723-153723
Closed Access | Times Cited: 111
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Benjamin Goldenson, Pooja Hor, Dan S. Kaufman
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
Kevin Nishimoto, Taylor Barca, Aruna Azameera, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 2
Open Access | Times Cited: 81
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Marco Ruella, Felix Korell, Patrizia Porazzi, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 976-995
Open Access | Times Cited: 60
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Xiaomeng Hu, Karl Manner, Rowena DeJesus, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Kaveh Hadiloo, Safa Tahmasebi, Abdolreza Esmaeilzadeh
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 52
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
Eileen McGowan, Qimou Lin, Guocai Ma, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 121, pp. 109625-109625
Open Access | Times Cited: 123
Engineered off-the-shelf therapeutic T cells resist host immune rejection
Feiyan Mo, Norihiro Watanabe, Mary K. McKenna, et al.
Nature Biotechnology (2020) Vol. 39, Iss. 1, pp. 56-63
Open Access | Times Cited: 116
Next-generation cell therapies: the emerging role of CAR-NK cells
Rafet Başar, May Daher, Katayoun Rezvani
Blood Advances (2020) Vol. 4, Iss. 22, pp. 5868-5876
Open Access | Times Cited: 110
Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy
Alvin J. Mukalel, Rachel Riley, Rui Zhang, et al.
Cancer Letters (2019) Vol. 458, pp. 102-112
Open Access | Times Cited: 103
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
Eytan Herzig, Kaman Chan Kim, Thomas Packard, et al.
Cell (2019) Vol. 179, Iss. 4, pp. 880-894.e10
Open Access | Times Cited: 96
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani, Afshin Derakhshani, Omid Kooshkaki, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8305-8305
Open Access | Times Cited: 85
BiTEs better than CAR T cells
Marion Subklewe
Blood Advances (2021) Vol. 5, Iss. 2, pp. 607-612
Open Access | Times Cited: 84
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
Tianqing Xin, Cheng Li, Chuchao Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 62
Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
Daniel Vasic, Jong Bok Lee, Y.K. Leung, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Closed Access | Times Cited: 50
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
Mika L. Persson, Alicia M. Douglas, Frank Alvaro, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 9, pp. 1408-1422
Open Access | Times Cited: 49
Gamma delta (γδ) T cells in cancer immunotherapy; where it comes from, where it will go?
Jiechu Deng, Hongna Yin
European Journal of Pharmacology (2022) Vol. 919, pp. 174803-174803
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top